Diagnostic Kits/Diagnosis or drug- Will pharmaceutical companies or diagnostics manufacturers earn more from personalized medicine
Jump to navigation
Jump to search
Kling. Diagnosis or drug? Will pharmaceutical companies or diagnostics manufacturers earn more from personalized medicine? EMBO reports (2007) vol. 8 (10) pp. 903-6. Accessed December 14, 2009 at http://www.nature.com/embor/journal/v8/n10/full/7401080.html
- focuses on Genomic Health's Oncotype DX test (based on expression levels) - predicts recurrence of breast cancer
- also mentions Roche's AmpliChip (based on CYP2D6 and CYP2C19 genes) - predicts drug metabolism
- and XDx AlloMap (based on expression levels) - predicts heart transplant rejection
- and Applied Genomics MammoStrat test (based on antibodies) - predicts recurrence of a particular breast cancer
- 70% of clinical decisions made by physicians in US are based on diagnostics (not necessarily GDx), but only 2% of $2 trillion annually spent on healthcare goes into diagnostics
- Clinically validating a test is probably "the biggest barrier to progress" says Doug Ross, Chief Scientific Officer of Applied Genomics.
- Genomic Health's Oncotype DX test was clinically validated with samples from the National Surgical Adjuvant Breast and Bowel Foundation (NSABP).
- "Genomic Health's competitive advantage in the marketplace is derived in large part from the strength of the data from their published NSABP results," says Ross.
- so sharing of tissue samples for clinical trials to validate a GDx could be an important force encouraging collaboration.